After the U.S. Supreme Court issued its unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., Chad Landmon was quoted extensively in legal, intellectual property and life sciences publications examining the ruling and its significance for the pharmaceutical industry. His commentary addressed the Court's reaffirmation of the skinny-label pathway, its clarification of induced infringement standards and the decision's implications for future Hatch-Waxman litigation and pharmaceutical patent strategy.

See media coverage below.

Hikma v Amarin: Six takeaways from the pivotal ruling
Life Sciences Intellectual Property Review